Chemoablation is an emerging treatment for urothelial carcinomas. This review provides an overview of the evidence for intracavitary chemoablation in the treatment of urothelial carcinomas. The benefits of such agents include a reduction in morbidity and diseased organ preservation.
While numerous agents have shown promise, research is limited due to small patient cohorts, varying follow-up, and no standardized methodology to assess response. Therefore, to date, chemoablation has not been widely adopted. This may change as a novel mitomycin formulation has recently been approved for treating low-grade UTUC. Future studies are ongoing which evaluate other promising chemoablation options in urothelial carcinoma.
Urology. 2020 Jun 12 [Epub ahead of print]
Muhannad Alsyouf, Phillip Pierorazio, Jason Groegler, Brian Hu
Department of Urology, Loma Linda University Health, Loma Linda, CA. Electronic address: ., Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD. Electronic address: ., Department of Urology, Loma Linda University Health, Loma Linda, CA. Electronic address: ., Department of Urology, Loma Linda University Health, Loma Linda, CA. Electronic address: .
PubMed http://www.ncbi.nlm.nih.gov/pubmed/32540302